Join us on the latest episode! Our Guest: Javier Swarcberg, CEO of Spruce Biosciences

What you'll get out of this episode:

• Dive deep into the world of Congenital Adrenal Hyperplasia (CAH) treatments and drug development.
• Understand the challenges and rewards of addressing rare diseases, especially in pediatrics.
• Javier Szwarcberg discusses Spruce's innovative Tildesophon and its potential impact on the CAH therapeutic landscape.
• Discover the upcoming clinical updates from Spruce Biosciences and the promising future outlook for CH treatments.

To learn more about Spruce Biosciences: https://sprucebio.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/